DURHAM, N.C., July 8, 2026
GeneCentric has announced the launch of ExpressCT Rewind™, a retrospective fragmentomics analysis service designed to unlock gene expression insights from existing liquid biopsy DNA sequencing datasets. The new service applies the company’s proprietary ExpressCT™ analytical pipeline to previously generated sequencing data, including commercial comprehensive genomic profiling (CGP) panels, allowing biopharmaceutical companies and academic researchers to uncover valuable biological information without collecting additional patient samples or changing established laboratory workflows. By extracting gene expression signals from archived cell-free DNA (cfDNA) sequencing data, ExpressCT Rewind enables researchers to generate customized biomarker signatures that may predict treatment response, improve patient stratification, and support oncology drug development while maximizing the value of existing clinical trial and biobank datasets.
Fragmentomics Adds a New Biological Dimension Beyond Mutation Profiling
Unlike conventional liquid biopsy analyses that primarily focus on identifying genetic mutations, ExpressCT Rewind leverages fragmentomics to infer gene expression patterns embedded within cfDNA sequencing data. According to GeneCentric, every archived liquid biopsy dataset represents an untapped opportunity to reveal biological insights that mutation profiling alone cannot capture. Company President and Chief Executive Officer Michael Milburn, Ph.D., said the platform enables researchers to revisit completed clinical trials and archived sequencing runs to extract a second dimension of biology, providing new opportunities for translational research and biomarker discovery. For pharmaceutical developers that have already invested heavily in patient enrollment, sample collection, and sequencing, the technology offers a cost-effective approach to generate additional clinical value from existing datasets while avoiding the expense and complexity of new sample collection.
Technology Supports Biomarker Discovery and Precision Oncology Research
ExpressCT Rewind has been developed to help researchers evaluate virtually any gene expression marker of interest across patient cohorts, supporting applications including patient selection, clinical trial design, correlative biomarker studies, and precision oncology research. GeneCentric reported that findings presented at AACR 2026 and other leading oncology conferences demonstrated the platform’s ability to extend the utility of comprehensive genomic profiling beyond mutation analysis by building novel prognostic models, identifying molecular subtypes, and quantifying the liquid expression of important therapeutic targets such as estrogen receptor (ER) and HER2. These capabilities provide researchers with additional molecular information that may improve understanding of tumor biology and help identify patients most likely to benefit from targeted therapies.
Advertisement
GeneCentric Strengthens Precision Medicine Platform for Drug Development
The introduction of ExpressCT Rewind further expands GeneCentric’s precision medicine platform, which is focused on bringing gene expression biology into routine liquid biopsy testing through advanced fragmentomics technology. Backed by more than a decade of expertise in gene expression analysis, the company’s ExpressCT™ platform is designed to identify clinically meaningful biomarkers that support preclinical research, clinical drug development, and commercial diagnostic applications. By enabling retrospective analysis of archived sequencing datasets, ExpressCT Rewind provides pharmaceutical companies and research institutions with an efficient pathway to enhance biomarker discovery, optimize oncology clinical trials, and accelerate the development of more personalized cancer therapies without disrupting existing laboratory operations. The launch reinforces GeneCentric’s strategy of advancing precision oncology through innovative diagnostic technologies that maximize the scientific value of liquid biopsy data.
Source: GeneCentric press release
